SCOTUS faces a new mifepristone showdown as Fifth Circuit challenges loom
TL;DR
Two pharma-backed cases—Danco Laboratories v. Louisiana and GenBioPro v. Louisiana—bring a new Supreme Court reckoning over mifepristone, the Fifth Circuit’s standing theory, and what relief a federal court may grant that could upend the FDA’s REMS and mail‑order access. The Court’s course may mirror its Alliance ruling, potentially preserving access while the policy framework evolves, but the decision remains uncertain amid abortion politics and jurisdiction questions.
Topics:nationpolitics#alliance-for-hippocratic-medicine#danco-laboratories-v-louisiana#fifth-circuit#mifepristone#politics#rems
- The Supreme Court gets thrown back into the abortion wars vox.com
- Supreme Court Temporarily Restores Access to Abortion Pill by Mail The New York Times
- Court issues temporary order allowing access to abortion pill by mail SCOTUSblog
- Supreme Court temporarily restores ability to receive abortion drug mifepristone by mail CNN
- A Radical Court Just Called Trump’s Abortion Bluff Slate
Want the full story? Read the original reporting
Read on vox.com